Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen Biotech - Additional Information (Details)

v3.19.3
Licensing and Other Arrangements - Janssen Biotech - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue from contracts with customers   $ 8,525,000 $ 775,000 $ 17,176,000 $ 3,518,000
Janssen [Member] | License Agreement [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
One-time payment $ 2,500,000        
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events $ 3,000,000        
Percentage of royalty on worldwide net sales of each product upon commercialization 0.75%        
Revenue from contracts with customers   2,500,000      
Contract assets   0   0  
Contract liabilities   0   0  
Capitalized contract costs   $ 0   $ 0